Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Influenza Male and female subjects in generally good health in the opinion of the investigator as determined by vital signs, medical history, and a physical exam based on medical history. 2. Subjects must be able to verbalize understanding of the consent form, provide written informed consent and verbalize willingness to complete study procedures. 3. Be 18 to 70 years of age (inclusive). 4. Subjects must weigh at least 50 kg and must have a Body Mass Index (BMI) of no greater than 40.00. 5. Febrile, oral temperature ≥100.4°F (≥38.0°C) in combination with symptoms 6. At least one respiratory symptom Cough Sore throat Wheezing Sneezing Shortness of breath Nasal congestion Earache Pleuritic chest pain 7. At least one constitutional symptom Headache  Have received any investigational drug or investigational vaccine within 8 weeks prior to study drug dosing. 2. Have had a serious adverse reaction or previous episode of anaphylaxis related to any drug. 3. Have received blood products within 6 months of study enrollment. 4. Have concurrent cystic fibrosis or emphysema. 5. Have sickle cell disease. 6. Known IGE mediated allergic response to lactose (not lactose intolerance). 7. Any history of congenital or acquired bleeding abnormalities. 8. Existence of any surgical, medical, or laboratory condition that, in the judgment of the clinical investigator, might interfere with the safety, distribution, metabolism or excretion of the drug. 9. Use of antiviral influenza medications within 10 days prior to screening (Subjects will be prohibited from taking antiviral influenza medications during the course of the trial). 10. Current clinical evidence of a recognized or suspected uncontrolled non-influenza infectious illness with onset prior to screening. 11. Known hypersensitivity to DAS181. 12. Women who are pregnant (urine pregnancy test), who are attempting to become pregnant, or who are breast-feeding. 13. Uncontrolled seizure disorder or history of seizure activity within 12 months prior to study participation. 14. Any significant findings in the subject's medical history or physical examination that, in the opinion of the investigator, would affect subject safety or compliance with the dosing schedule. 15. Subjects with history of asthma or chronic obstructive pulmonary disease (COPD) requiring the use of acute or chronic medication in the past 3 years. 16. Subjects with acute diagnosis of a chronic medical condition within the last 3 months. 17. Subjects with a chronic medical condition that have initiated or changed dosing or regimen of prescription medications to treat the chronic medical condition within the last 3 months. (Any changes in chronic medications during the 28 day enrollment period will be captured in the source documentation under concomitant medications). 18. Subjects with current or previous history of the following: systemic disorders, immunological disorders, hepatitis B virus (HBV), hepatitis C virus (HCV) or cirrhosis, transplant recipients, or other immunosuppressive illness. 19. Subjects with cancer or history of hematologic malignancy. Cancer is defined as any active neoplastic diseases excluding noninvasive basal cell carcinoma. 20. Subjects who have had or are scheduled to have surgery within 30 days of initiation of the study. 21. Subjects who have donated or lost more than 500 mL of blood in the two months prior to screening. 22. Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance. 23. Family members of site staff directly involved in study conduct are excluded from study participation. 24. Subjects with an oxygen saturation (Sa02) level of <92% as measured by pulse oximeter. 25. Subjects with a modified CURB-65 score of 2 or higher